Anti-Diabetes Drugs segment revenues Poland 2016-2028

The revenue in the 'Anti-Diabetes Drugs' segment of the pharmaceuticals market in Poland was forecast to continuously increase between 2024 and 2028 by a total of 50 million U.S. dollars (+21.73 percent). After the twelfth consecutive year of increase, the indicator is estimated to reach 280.16 million U.S. dollars and, therefore, a new peak in 2028. Notably, the revenue of the 'Anti-Diabetes Drugs' segment of the pharmaceuticals market continuously increased over the past years.

Revenue in the Anti-Diabetes Drugs segment in Poland from 2016 to 2028 (in million U.S. dollars)

Characteristic	In million U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Citation formats